Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)

Alterations of p53 signalling pathway is the most frequent event in human cancers. About 50% of these, albeit showing wild-type p53, have flaws in the control mechanisms of p53 levels and activity. MDM2 and MDMX (MDM4) are the main negative regulators of p53. The relevance of MDM2 on the regulation of p53 levels and activity has fostered the development of strategies aimed at restoring p53 functions by blocking the physical interaction between MDM2 and p53. As a consequence, a number of different small molecules and peptidomimetics have been disclosed in the last decade as inhibitors of MDM2/p53 interaction. Recent studies, however, have thrust MDMX into the limelight as an additional chemotherapeutic target, suggesting the presence of a more complex relationship between MDM2, MDMX and p53. In this review article, we report key aspects of MDMX-mediated regulation of p53, recent advances in the structural characterization of the protein, and the progress made so far in the medicinal chemistry of MDMX ligands.

[1]  M. Loda,et al.  Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer , 2006, Molecular Cancer Research.

[2]  H. Schünemann,et al.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties , 2008, Journal of Molecular Medicine.

[3]  A. Jochemsen,et al.  Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53* , 2002, The Journal of Biological Chemistry.

[4]  Chandra S Verma,et al.  Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies , 2010, Cell cycle.

[5]  F. Mancini,et al.  Mitochondrial MDM4 (MDMX): An unpredicted role in the p53-mediated intrinsic apoptotic pathway , 2009, Cell cycle.

[6]  R. Eils,et al.  Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis , 2007, Hepatology.

[7]  M. Alonso,et al.  Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. , 2005, American journal of clinical pathology.

[8]  Charles A. Thomas,et al.  The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell‐cycle‐inhibitory function induces tumorigenesis , 1998, The EMBO journal.

[9]  D. Neal,et al.  High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53 , 2008, Clinical Cancer Research.

[10]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[11]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[12]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[13]  M. Jackson,et al.  MdmX Protects p53 from Mdm2-Mediated Degradation , 2000, Molecular and Cellular Biology.

[14]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[15]  Gabriele Cruciani,et al.  Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition , 2008, J. Chem. Inf. Model..

[16]  Chong Li,et al.  A left-handed solution to peptide inhibition of the p53-MDM2 interaction. , 2010, Angewandte Chemie.

[17]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[18]  Kristian Helin,et al.  Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.

[19]  S. De Clercq,et al.  Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo , 2010, Molecular and Cellular Biology.

[20]  B. Gallie,et al.  Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma. , 2008, Biochemical and biophysical research communications.

[21]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[22]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[23]  K. Jordan-Sciutto,et al.  The E2F‐1 transcription factor is negatively regulated by its interaction with the MDMX protein , 2003, Journal of cellular biochemistry.

[24]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[25]  Elizabeth A. Harker,et al.  In Silico Improvement of beta3-peptide inhibitors of p53 x hDM2 and p53 x hDMX. , 2009, Journal of the American Chemical Society.

[26]  Toshiaki Hara,et al.  N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53. , 2009, Bioorganic & medicinal chemistry.

[27]  S. Berberich,et al.  MdmX Represses E2F1 Transactivation , 2004, Cell cycle.

[28]  I. Ellis,et al.  The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers , 2010, The Journal of pathology.

[29]  Xueliang Fang,et al.  Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. , 2006, Journal of medicinal chemistry.

[30]  R. Ramirez-Solis,et al.  mdmx is a negative regulator of p53 activity in vivo. , 2002, Cancer research.

[31]  Heather A Carlson,et al.  Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. , 2007, Journal of the American Chemical Society.

[32]  Tina N. Davis,et al.  A stapled p53 helix overcomes HDMX-mediated suppression of p53. , 2010, Cancer cell.

[33]  F. Mancini,et al.  Puzzling over MDM4-p53 network. , 2010, The international journal of biochemistry & cell biology.

[34]  G. Dubin,et al.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx , 2009, Cell cycle.

[35]  C. Prives,et al.  Susceptibility of p53 Unstructured N Terminus to 20 S Proteasomal Degradation Programs the Stress Response*♦ , 2009, The Journal of Biological Chemistry.

[36]  Geng-Hung Liu,et al.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  N. Little,et al.  Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms , 2001, EMBO reports.

[38]  Peter M Fischer,et al.  Small-molecule inhibitors of MDM2 as new anticancer therapeutics. , 2010, Seminars in cancer biology.

[39]  M. Chalfie,et al.  Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. , 2003, Molecular cell.

[40]  S. Francoz,et al.  Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Yolande F M Ramos,et al.  Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. , 2001, Cancer research.

[42]  Sharmila Patel,et al.  Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer , 2008, Expert opinion on investigational drugs.

[43]  R. Singh,et al.  Turning the RING Domain Protein MdmX into an Active Ubiquitin-Protein Ligase* , 2010, The Journal of Biological Chemistry.

[44]  A. Kentsis,et al.  The Mdm2 RING domain C‐terminus is required for supramolecular assembly and ubiquitin ligase activity , 2007, The EMBO journal.

[45]  D. Bashford,et al.  Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.

[46]  R. Deshaies,et al.  RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.

[47]  John K. Buolamwini,et al.  A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis , 2010, Molecular Cancer Therapeutics.

[48]  Jean-Christophe Marine,et al.  Mdmx as an essential regulator of p53 activity. , 2005, Biochemical and biophysical research communications.

[49]  D. Parks,et al.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.

[50]  S. Berberich,et al.  Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation. , 2003, Biochemistry.

[51]  A. Fersht,et al.  Structure of human MDM4 N-terminal domain bound to a single-domain antibody. , 2008, Journal of molecular biology.

[52]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[53]  R. Pellicciari,et al.  MDM2/MDMX inhibitor peptide: WO2008106507 , 2009, Expert opinion on therapeutic patents.

[54]  Yolande F M Ramos,et al.  Comparative study of the p53-mdm2 and p53-MDMX interfaces , 1999, Oncogene.

[55]  Min Liu,et al.  Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. , 2010, Journal of molecular biology.

[56]  A. Fersht,et al.  Solution structure of the C4 zinc finger domain of HDM2 , 2006, Protein science : a publication of the Protein Society.

[57]  Gareth Davies,et al.  MDM4 binds ligands via a mechanism in which disordered regions become structured , 2010, FEBS letters.

[58]  Guillermina Lozano,et al.  Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities , 2008, Molecular Cancer Research.

[59]  Steffen Hauptmann,et al.  Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis , 2005, International journal of cancer.

[60]  A. Ciechanover,et al.  HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Ringnér,et al.  Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.

[62]  S. Korsmeyer,et al.  Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide , 2007 .

[63]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[64]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[65]  G. Gaidano,et al.  MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild‐type CLL with a poor cytotoxic response to Nutlin‐3 , 2010, British journal of haematology.

[66]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[67]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[68]  Nathan Brown,et al.  Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction. , 2009, Methods in molecular biology.

[69]  Chad Deisenroth,et al.  Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation , 2006, Molecular and Cellular Biology.

[70]  Do-Hyoung Kim,et al.  Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. , 2006, Journal of combinatorial chemistry.

[71]  M. Alonso,et al.  Real-Time Quantitative PCR Analysis of Regions Involved in Gene Amplification Reveals Gene Overdose in Low-Grade Astrocytic Gliomas , 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[72]  Alanna Schepartz,et al.  Beta-peptides with improved affinity for hDM2 and hDMX. , 2009, Bioorganic & medicinal chemistry.

[73]  Baoli Hu,et al.  Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.

[74]  Y. Arai,et al.  Genome‐wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma , 2010, Genes, chromosomes & cancer.

[75]  G. Wahl,et al.  Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo , 2006, Cell Death and Differentiation.

[76]  Chong Li,et al.  Apamin as a template for structure-based rational design of potent peptide activators of p53. , 2009, Angewandte Chemie.

[77]  Jeremy R Stuart,et al.  DNA Damage-induced MDMX Degradation Is Mediated by MDM2* , 2003, Journal of Biological Chemistry.

[78]  S. Nicosia,et al.  Bing De Ling, a Chinese herbal formula, inhibits cancer cells growth via p53. , 2010, Frontiers in bioscience.

[79]  K. Vousden,et al.  An essential function of the extreme C‐terminus of MDM2 can be provided by MDMX , 2007, The EMBO journal.

[80]  M. Wolter,et al.  Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. , 1999, Cancer research.

[81]  A. Marchetti,et al.  MDM4 (MDMX) localizes at the mitochondria and facilitates the p53‐mediated intrinsic‐apoptotic pathway , 2009, The EMBO journal.

[82]  G. Wahl,et al.  Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.

[83]  C. Houdayer,et al.  RB1 and TP53 pathways in radiation-induced sarcomas , 2007, Oncogene.

[84]  T. Holak,et al.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.

[85]  Shih-Yin Tsai,et al.  Emerging roles of E2Fs in cancer: an exit from cell cycle control , 2009, Nature Reviews Cancer.

[86]  A. Levine,et al.  Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. , 2010, Genes & cancer.

[87]  F. Mancini,et al.  MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts , 2002, Oncogene.

[88]  Wei Wang,et al.  Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.

[89]  V. Pant,et al.  Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. , 2010, Cancer research.

[90]  M. Geiser,et al.  Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes* , 2009, Journal of Biological Chemistry.

[91]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[92]  D. Vaux,et al.  Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans , 2008, Cell Death and Differentiation.

[93]  R. Pellicciari,et al.  Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition , 2009, Proteins.

[94]  Michael A. Dyer,et al.  MDMX: from bench to bedside , 2007, Journal of Cell Science.

[95]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[96]  A. Braun,et al.  Gene expression profiling of metastatic brain cancer. , 2007, Oncology reports.

[97]  Jared K Burks,et al.  The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias , 2010, Molecular Cancer Therapeutics.

[98]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[99]  Guillermina Lozano,et al.  High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. , 2007, Human pathology.

[100]  K. Helin,et al.  Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.

[101]  J. Marine Pharmacological rescue of p53 in cancer therapy: widening the sensitive tumor spectrum by targeting MDMX. , 2010, Cancer cell.

[102]  D. Koley,et al.  Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system. , 2010, Bioorganic & medicinal chemistry.